|
|
|
|
Investor calls for Genzyme divestments
Should Genzyme pare away at its business?That's what a key investor is saying? Ralph Whitworth, chief of Relational Investors and Genzyme-director-in-waiting, told Bloomberg that he thinks the company's renal business should be sold off. That way,...
|
|
|
Genzyme investor wants some businesses sold
NEW YORK - Genzyme Corp., the worlds largest maker of genetic disease drugs, should sell businesses that do not focus in that area, said Ralph Whitworth, the head of Relational Investors LLC.Genzymes renal business, which includes Renagel and Renvela,...
|
|
|
Genzyme Reports Fourth-Quarter Revenue
Outlines Progress Made in 2009 and Outlook for 2010 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 12, 2010 - Genzyme Corp.(NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008...
|
|
|
Genzyme Reports Fourth-Quarter Revenue
CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Genzyme Corp.(NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compared with $4.6...
|
|
|
Genzyme Q4 Revenue Down, Yet In Line - Update
(RTTNews) - Biotechnology company Genzyme Corp.(GENZ) said Tuesday its revenue for the fourth-quarter declined from last year, impacted by the product supply interruption in its genetic disease business. Nevertheless, revenues for the fourth quarter came...
|
|
|
Genzyme Q4 Revenue Down, Yet In Line - Update
(RTTNews) - Biotechnology company Genzyme Corp.(GENZ) said Tuesday its revenue for the fourth-quarter declined from last year, impacted by the product supply interruption in its genetic disease business. Nevertheless, revenues for the fourth quarter came...
|
|
|
Genzyme Reports Fourth-Quarter Revenue
Companies mentioned in this article: Genzyme Corporation CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Genzyme Corp. (NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008.
|
|
|
Genzyme Q4 Revenue Down, Yet In Line
1/12/2010 3:04 PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Biotechnology company Genzyme Corp.(GENZ: News ) said Tuesday its revenue for the fourth-quarter declined from last year, impacted by the product supply interruption in its genetic disease...
|
|
|
Genzyme Reports Fourth-Quarter Revenue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp.(NASDAQ: GENZ - News) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compared with $4...
|
|
|
Genzyme Reports Fourth-Quarter Revenue
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); CAMBRIDGE, Mass.- (Business Wire) Genzyme Corp. (NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008.
|
|
|
Genzyme Reports Fourth-Quarter Revenue
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); CAMBRIDGE, Mass.- (Business Wire) Genzyme Corp. (NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008.
|
|
|
Genzyme Reports Fourth-Quarter Revenue
CAMBRIDGE, Mass.(Business Wire) -- Genzyme Corp. (NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compared with $4.6...
|
|
|
Genzyme Reports Fourth-Quarter Revenue
Genzyme Corp.(NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compared with $4.6 billion in 2008. Excluding the Genetic...
|
|
|
Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral Metabolism Practice Patterns Around the Globe
/PRNewswire via COMTEX/ ---- BioTrends Research Group, Inc.recently released its TreatmentTrends(R): US Nephrology, EU Nephrology, and Canadian Nephrology publications. Each syndicated report offers comprehensive insight into the management of bone and...
|
|
|
Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral
EXTON, Pa., Jan.7 /PRNewswire/ -- BioTrends Research Group, Inc. recently released its TreatmentTrends: US Nephrology, EU Nephrology, and Canadian Nephrology publications. Each syndicated report offers comprehensive insight into the management of bone...
|
|
|
Analyst Choice Market Review on Companies Basic Materials and Healthcare Sectors
(Source: MARKETWIRE)Crude oil, merger & acquisition news, commodities prices led the US market high on Monday.The Dow gained 1.50%, the Standard & Poor's 500 rose 1.60% andthe NASDAQ jumped 1.73%. This drove us to do research on the following 6...
|
|
|
Analyst Choice Market Review on Companies Basic Materials and Healthcare Sectors
(MARKETWIRE via COMTEX) ----Crude oil, merger & acquisition news, commodities prices led the US market high on Monday.The Dow gained 1.50%, the Standard & Poor's 500 rose 1.60% andthe NASDAQ jumped 1.73%. This drove us to do research on the...
|
|
|
Analyst Choice Market Review on Companies Basic Materials and Healthcare Sectors NOTE TO EDITORS: The Followin
NEW DELHI, INDIA -- (MARKET WIRE) -- 01/06/10 -- Crude oil, merger & acquisition news, commodities prices led the US market high on Monday.The Dow gained 1.50%, the Standard & Poor's 500 rose 1.60% andthe NASDAQ jumped 1.73%. This drove us...
|
|
|
Analyst Choice Market Review on Companies Basic Materials and Healthcare Sectors NOTE TO EDITORS: The
Market Review on Companies Basic Materials and Healthcare Sectors NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Analyst Choice Get the latest news with our RSS feed Choice Market Review on Companies Basic Materials and Healthcare...
|
|
|
Analyst Choice Market Review on Companies Basic Materials and Healthcare Sectors
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Analyst Choice NEW DELHI, INDIA--(Marketwire - 01/06/10) - Crude oil, merger & acquisition news, commodities prices led the US market high on Monday.The Dow gained 1.50%, the...
|
|
|
Renvela
ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia,...
|
|
|
Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
Genzyme Corporation announced that the European Medicines Agencys Committee for Human Medicinal Products has adopted a positive opinion for the marketing authorization of the new phosphate binder Renvela for use in patients with chronic ki Genzyme...
|
|
|
Week of Nov. 23, 2009: Pfizer Collaborates to Fight Neglected Diseases; Patheon Names VP of Puerto Rico Operat
ePT--the Electronic Newsletter of Pharmaceutical Technology Company notes The Almac Group (Craigavon, UK) completed a 67,000-ft2 expansion to its Durham, North Carolina, facility, which now houses both the Clinical Services and Diagnostics Divisions.The...
|
|
|
Genzyme's phase 2/3 trial of advanced phosphate binder meets primary endpoint
Genzyme Corporation reported results of a phase-2/3 study of its advanced phosphate binder (APB).The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a...
|
|
|
Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
CAMBRIDGE, Mass., Nov.18, 2009- Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively...
|
